ML19217A258

Export License Issued to Cambridge Isotope Laboratories, Inc. XMAT449

ML19217A258
Person / Time
Site:	11006350
Issue date:	08/02/2019
From:	Peter Habighorst NRC/OIP
To:	Ionta G Cambridge Isotope Labs
Savoy J
References
Download: ML19217A258 (8)

Text

EXPORT LICENSE NRC LICENSE NO.: XMAT449 United States of America Page 1 of 8 Nuclear Regulatory Commission NRC DOCKET NO.: 11006350 Washington, D.C. 20555 LICENSE EXPIRES: May 31, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.

LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)

Cambridge Isotope Laboratories, Inc. See following page(s) 50 Frontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) OTHER U.S. PARTY(IES) TO EXPORT See following page(s) Cambridge Isotope Laboratories, Inc.

50 Frontage Road Andover, MA 01810 (supplier/distributor)

APPLICANT'S

REFERENCE:

Application Dated 03/27/2019 ULTIMATE DESTINATION: United Kingdom QUANTITY(IES) DESCRIPTION OF MATERIAL(S) OR FACILITY(IES) 10,000 kilograms Deuterium in the form of deuterium oxide, deuterium gas, and other compounds.

Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as Peter J. Digitally signed by Peter J.

Habighorst amended, and the Energy Reorganization Act of 1974. SIGNATURE: Habighorst Date: 2019.08.02 11:12:21 -04'00' This license is subject to the right of recapture or control NAME AND TITLE: Peter J. Habighorst, Acting Deputy Director by Section 108 of the Atomic Energy Act of 1954, as Office of International Programs amended, and to all the other provisions of said Acts, now August 02, 2019 or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE:

the NRC.

EXPORT LICENSE

XMAT449 Page 2 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

2.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

3.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

4.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

5.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

6.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

7.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

8.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 3 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

9.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

10.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

11.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

12.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

13.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

14.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

15.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

16.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 4 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

17.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

18.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

19.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

20.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

21.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

22.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

23.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

24.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 5 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

25.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

26.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

27.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

28.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

29.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

30.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

31.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

32.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 6 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

33.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

34.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

35.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

36.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

37.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

38.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

39.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

40.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 7 of 8 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

41.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

42.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

43.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

44.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

45.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

46.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

47.

(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)

XMAT449 Page 8 of 8 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):

1.

(for distribution to ultimate consignees)

2.

(for distribution to ultimate consignees)

3.

(for distribution to ultimate consignees)

4.

(for distribution to ultimate consignees)

5.

(for distribution to ultimate consignees)

6.

(for distribution to ultimate consignees)